Treatment of Extended Spectrum Betalactamase Producing Bacteria Causing Urinary Tract Infections in General Practice
NCT ID: NCT01531023
Last Updated: 2016-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
168 participants
OBSERVATIONAL
2013-04-30
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study hypothesis is to assess the clinical and microbiological outcome of pivmecillinam treatment of ESBL producing E. coli and K. Pneumoni, as well as to observe the clinical and microbiological outcome of the same group of bacteria treated with other antiinfectious agents.
Samples are gathered in primary care setting.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ESBL producing E. coli bacteria
Group of patients with identified ESBL producing E.coli in a urine sample taken in a primary care setting.
No interventions assigned to this group
Non-ESBL E.coli urinary tract infection
E.coli bacteria found in the setting of a urinary tract infection in a primary care setting where ESBL producing bacteria are not found.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Above age 16.
Exclusion Criteria
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital of North Norway
OTHER
St. Olavs Hospital
OTHER
Helse Stavanger HF
OTHER_GOV
The Hospital of Vestfold
OTHER
Vestre Viken Hospital Trust
OTHER
University Hospital, Akershus
OTHER
Unilabs
UNKNOWN
University of Oslo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marianne Bollestad
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Morten Lindbaek, Md PhD
Role: STUDY_DIRECTOR
University of Oslo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vestre Viken Hospital Trust
Bærum, , Norway
University Hospital Akershus
Lørenskog, , Norway
Unilabs
Skien, , Norway
Helse Stavanger HF
Stavanger, , Norway
University Hospital of North Norway
Tromsø, , Norway
St Olavs Hospital
Trondheim, , Norway
Vestfold Hospital Trust
Tønsberg, , Norway
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bollestad M, Grude N, Solhaug S, Raffelsberger N, Handal N, Nilsen HS, Romstad MR, Emmert A, Tveten Y, Soraas A, Jenum PA, Jenum S, Moller-Stray J, Weme ET, Lindbaek M, Simonsen GS; (the Norwegian ESBL UTI study group). Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study. J Antimicrob Chemother. 2018 Sep 1;73(9):2503-2509. doi: 10.1093/jac/dky230.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011/2214-3
Identifier Type: -
Identifier Source: org_study_id